Antigenicity study of the yeast-generated human parvovirus 4 (PARV4) virus-like particles

Lazutka, Justas; Simutis, Karolis; Matulis, Paulius; Petraitytė-Burneikienė, Rasa; Kučinskaitė-Kodzė, Indrė; Simanavičius, Martynas; Tamošiūnas, Paulius Lukas

doi:10.1016/j.virusres.2020.198236

Cited by 3 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it is known that capsid proteins of various virus types, when expressed in yeast cells, can form not amorphous aggregates and/or amyloid structures but virus-like particles-prototypical capsids consisting of only one type of protein. See, e.g., [212]. Moreover, viral factories (viral inclusions) are known to be structures in which viral particle formation, rather than utilization of viral capsid proteins, occurs.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Saccharomyces cerevisiae as a Model for Studying Human Neurodegenerative Disorders: Viral Capsid Protein Expression

Bayandina,

Mukha

2023

IJMS

View full text Add to dashboard Cite

In this article, we briefly describe human neurodegenerative diseases (NDs) and the experimental models used to study them. The main focus is the yeast Saccharomyces cerevisiae as an experimental model used to study neurodegenerative processes. We review recent experimental data on the aggregation of human neurodegenerative disease-related proteins in yeast cells. In addition, we describe the results of studies that were designed to investigate the molecular mechanisms that underlie the aggregation of reporter proteins. The advantages and disadvantages of the experimental approaches that are currently used to study the formation of protein aggregates are described. Special attention is given to the similarity between aggregates that form as a result of protein misfolding and viral factories—special structural formations in which viral particles are formed inside virus-infected cells. A separate part of the review is devoted to our previously published study on the formation of aggregates upon expression of the insect densovirus capsid protein in yeast cells. Based on the reviewed results of studies on NDs and related protein aggregation, as well as viral protein aggregation, a new experimental model system for the study of human NDs is proposed. The core of the proposed system is a comparative transcriptomic analysis of changes in signaling pathways during the expression of viral capsid proteins in yeast cells.

show abstract

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Saccharomyces cerevisiae as a Model for Studying Human Neurodegenerative Disorders: Viral Capsid Protein Expression

Bayandina,

Mukha

2023

IJMS

View full text Add to dashboard Cite

show abstract

Parvovirus B19V, Bocaviruses, and Other Human Parvoviruses

Söderlund‐Venermo

2023

ClinMicroNow

View full text Add to dashboard Cite

Parvoviruses are small, nonenveloped icosahedral viruses with a linear single‐stranded‐DNA (ssDNA) genome in the family Parvoviridae in the realm Monodnaviria . The family Parvoviridae is divided into three subfamilies, Parvovirinae , Densovirinae , and the new Hamaparvovirinae , on the basis of their ability to infect vertebrates, invertebrates, or both, respectively, and their NS1 amino acid sequences. The first human parvoviruses identified were the nonpathogenic adeno‐associated viruses of the genus Dependoparvovirus , which are increasingly used in gene therapy. Human bocavirus (HBoV1) has the typical structure of a member of the Parvoviridae . The most common test for diagnosis of HBoV1 infection is DNA detection by qualitative PCR. Parvoviruses are unable to induce cells to divide, so they require actively dividing cells for their replication.

show abstract

Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery

et al. 2023

View full text Add to dashboard Cite

Virus-like particles (VLPs) are empty, nanoscale structures morphologically resembling viruses. Internal cavity, noninfectious, and particulate nature with a high density of repeating epitopes, make them an ideal platform for vaccine development and drug delivery. Commercial use of Gardasil-9 and Cervarix showed the usefulness of VLPs in vaccine formulation. Further, chimeric VLPs allow the raising of an immune response against different immunogens and thereby can help reduce the generation of medical or clinical waste. The economically viable production of VLPs significantly impacts their usage, application, and availability. To this end, several hosts have been used and tested. The present review will discuss VLPs produced using different yeasts as fermentation hosts. We also compile a list of studies highlighting the expression and purification of VLPs using a yeast-based platform. We also discuss the advantages of using yeast to generate VLPs over other available systems. Further, the issues or limitations of yeasts for producing VLPs are also summarized. The review also compiles a list of yeast-derived VLP-based vaccines that are presently in public use or in different phases of clinical trials.

show abstract

Antigenicity study of the yeast-generated human parvovirus 4 (PARV4) virus-like particles

Cited by 3 publications

References 43 publications

Saccharomyces cerevisiae as a Model for Studying Human Neurodegenerative Disorders: Viral Capsid Protein Expression

Saccharomyces cerevisiae as a Model for Studying Human Neurodegenerative Disorders: Viral Capsid Protein Expression

Parvovirus B19V, Bocaviruses, and Other Human Parvoviruses

Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery

Contact Info

Product

Resources

About